Search

Your search keyword '"Herrlinger U"' showing total 610 results

Search Constraints

Start Over You searched for: Author "Herrlinger U" Remove constraint Author: "Herrlinger U"
610 results on '"Herrlinger U"'

Search Results

1. Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial

2. PL01.4.A LATE BREAKING ABSTRACT: A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA

3. Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report

4. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development

5. 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab

6. 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study

7. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

9. P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma

12. 440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase

14. Proliferative potential and the inflammatory tumour microenvironment in meningioma correlate with neurological function at presentation, and anatomical location – from convexity to skull base and spine

15. Benchmarking of safety indicators for surgical treatment of brain metastases combined with intraoperative radiotherapy – Results of a prospective observational study with comparative matched-pair analysis

21. Artificial intelligence for the differentiation between multiple sclerosis and glioma II° or III° using 18F-FET-PET imaging

23. PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

24. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

31. Measuring change in health-related quality of life

33. Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET PET

35. Abstracts

48. Prognostic factors and scores for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: results from a randomized phase III trial: V976

50. 372MO Melanoma leptomeningeal metastases: A European multicenter cohort

Catalog

Books, media, physical & digital resources